Latest Hi-Tech Pharmacal Co. (HITK) Headlines H
Post# of 3
Posted On: 03/13/2014 9:25:28 AM
Latest Hi-Tech Pharmacal Co. (HITK) Headlines
Hi-Tech Pharmacal Reports Sales of $59.9 Million for the Third Quarter Ended January 31, 2014
Business Wire - Tue Mar 11, 6:00AM CDT
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today reported results for the third fiscal quarter ended January 31, 2014.
Hi-Tech Pharmacal Has Returned 28.2% Since SmarTrend Recommendation (HITK)
Comtex SmarTrend(R) - Thu Mar 06, 11:06AM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 9 months, Hi-Tech Pharmacal has returned 28.22% as of today's recent price of $43.30.
Akorn Guidance Worries Street As Strategy Hits Delays
at Investor's Business Daily - Mon Mar 03, 4:30PM CST
Specialty drugmaker Akorn's Q4 earnings met estimates Monday, but its 2014 guidance and a new accounting problem halted the IBD 50 stock dead in its tracks. Akorn (AKRX) said profit totaled 14 cents a share, up a penny from the year-earlier quarter...
Akorn Q4 Meets But Guidance Disappoints, Stock Down
at Investor's Business Daily - Mon Mar 03, 9:07AM CST
Specialty drugmaker Akorn (AKRX) Monday reported a Q4 in line with estimates, but it guided 2014 below expectations and shares plummeted 15% in early trading in the stock market today. The company said profit totaled 14 cents a share, up a penny from...
Hi-Tech Pharmacal Shares Up 28.4% Since SmarTrend's Buy Recommendation (HITK)
Comtex SmarTrend(R) - Thu Feb 27, 9:43AM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 8 months, Hi-Tech Pharmacal has returned 28.40% as of today's recent price of $43.36.
Youngevity International (YGYI) Inks Consulting Agreement with Creative Memories Co-Founder Rhonda Kanning Anderson
Business Wire - Wed Feb 26, 7:05AM CST
Youngevity International, Inc. (OTCQX: YGYI) (www.YGYI.com), a global direct marketer of nutritional and lifestyle products and also a vertically-integrated producer of gourmet coffees for the commercial, retail and direct sales channels, announced today that Rhonda Kanning Anderson will immediately begin advising the company on expanding its product offering in Scrap Books, Photo Albums, and Memory Books in both the digital and paper formats. Rhonda will have a keen focus on helping build the Heritage Makers Brand in the area of digital scrap booking as well as assist in the development and marketing of more traditionally oriented products for this space.
Hi-Tech Pharmacal Up 28.3% Since SmarTrend Uptrend Call (HITK)
Comtex SmarTrend(R) - Wed Feb 12, 4:51PM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 8 months, Hi-Tech Pharmacal has returned 28.28% as of today's recent price of $43.32.
Actavis, Valeant, Jazz: New Roles For Specialty Pharma
at Investor's Business Daily - Fri Feb 07, 1:12PM CST
Last month, during an otherwise ho-hum conference call on 2014 financial guidance, Valeant Pharmaceuticals CEO Michael Pearson electrified the stock market by making an audacious promise. "Today we're introducing our sixth strategic initiative, which...
Hi-Tech Pharmacal awarded US FDA's approval for Bromfenac Ophthalmic Solution
M2 - Fri Jan 24, 4:40AM CST
US-based specialist pharmaceuticals company Hi-Tech Pharmacal Co Inc (NasdaqGS:HITK) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) final approval for its Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day).
Hi-Tech Pharmacal Receives Final Approval for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day)
Business Wire - Thu Jan 23, 6:00AM CST
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted final approval for the Company's Abbreviated New Drug Application, (ANDA) for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday (R) ophthalmic solution, 0.09%. The product is used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Hi-Tech plans to launch the product immediately.
Fish & Richardson Wins Patent Infringement Suit for Allergan Over Generic LUMIGAN® 0.01%
PR Newswire - Wed Jan 15, 3:50PM CST
Fish & Richardson announced today that it won an important Hatch-Waxman litigation for client Allergan, Inc. (NYSE: AGN) in a patent infringement suit against Sandoz Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Hi-Tech Pharmacal Co., Inc., Watson Laboratories, Inc., Watson Pharmaceuticals, Inc., and Watson Pharma, Inc. On January 14, 2014, the U.S. District Court for the Eastern District of Texas ruled that the defendants could not sell their generic versions of Allergan's popular LUMIGAN® (bimatoprost ophthalmic solution) 0.01% until Allergan's last patent expires in 2027.
Hi-Tech Pharmacal in $25M Medicaid settlement
AP - Thu Dec 26, 10:06AM CST
NEW YORK (AP) — Hi-Tech Pharmacal said Thursday that it will pay $25 million to resolve allegations that it overcharged the Texas Medicaid program.
Hi-Tech Pharmacal Reports Sales of $59.9 Million for the Third Quarter Ended January 31, 2014
Business Wire - Tue Mar 11, 6:00AM CDT
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK) today reported results for the third fiscal quarter ended January 31, 2014.
Hi-Tech Pharmacal Has Returned 28.2% Since SmarTrend Recommendation (HITK)
Comtex SmarTrend(R) - Thu Mar 06, 11:06AM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 9 months, Hi-Tech Pharmacal has returned 28.22% as of today's recent price of $43.30.
Akorn Guidance Worries Street As Strategy Hits Delays
at Investor's Business Daily - Mon Mar 03, 4:30PM CST
Specialty drugmaker Akorn's Q4 earnings met estimates Monday, but its 2014 guidance and a new accounting problem halted the IBD 50 stock dead in its tracks. Akorn (AKRX) said profit totaled 14 cents a share, up a penny from the year-earlier quarter...
Akorn Q4 Meets But Guidance Disappoints, Stock Down
at Investor's Business Daily - Mon Mar 03, 9:07AM CST
Specialty drugmaker Akorn (AKRX) Monday reported a Q4 in line with estimates, but it guided 2014 below expectations and shares plummeted 15% in early trading in the stock market today. The company said profit totaled 14 cents a share, up a penny from...
Hi-Tech Pharmacal Shares Up 28.4% Since SmarTrend's Buy Recommendation (HITK)
Comtex SmarTrend(R) - Thu Feb 27, 9:43AM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 8 months, Hi-Tech Pharmacal has returned 28.40% as of today's recent price of $43.36.
Youngevity International (YGYI) Inks Consulting Agreement with Creative Memories Co-Founder Rhonda Kanning Anderson
Business Wire - Wed Feb 26, 7:05AM CST
Youngevity International, Inc. (OTCQX: YGYI) (www.YGYI.com), a global direct marketer of nutritional and lifestyle products and also a vertically-integrated producer of gourmet coffees for the commercial, retail and direct sales channels, announced today that Rhonda Kanning Anderson will immediately begin advising the company on expanding its product offering in Scrap Books, Photo Albums, and Memory Books in both the digital and paper formats. Rhonda will have a keen focus on helping build the Heritage Makers Brand in the area of digital scrap booking as well as assist in the development and marketing of more traditionally oriented products for this space.
Hi-Tech Pharmacal Up 28.3% Since SmarTrend Uptrend Call (HITK)
Comtex SmarTrend(R) - Wed Feb 12, 4:51PM CST
SmarTrend identified an Uptrend for Hi-Tech Pharmacal (NASDAQ:HITK) on June 19th, 2013 at $33.77. In approximately 8 months, Hi-Tech Pharmacal has returned 28.28% as of today's recent price of $43.32.
Actavis, Valeant, Jazz: New Roles For Specialty Pharma
at Investor's Business Daily - Fri Feb 07, 1:12PM CST
Last month, during an otherwise ho-hum conference call on 2014 financial guidance, Valeant Pharmaceuticals CEO Michael Pearson electrified the stock market by making an audacious promise. "Today we're introducing our sixth strategic initiative, which...
Hi-Tech Pharmacal awarded US FDA's approval for Bromfenac Ophthalmic Solution
M2 - Fri Jan 24, 4:40AM CST
US-based specialist pharmaceuticals company Hi-Tech Pharmacal Co Inc (NasdaqGS:HITK) reported on Thursday the receipt of the US Food and Drug Administration's (FDA) final approval for its Abbreviated New Drug Application (ANDA) for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day).
Hi-Tech Pharmacal Receives Final Approval for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day)
Business Wire - Thu Jan 23, 6:00AM CST
Hi-Tech Pharmacal Co., Inc. (NASDAQ:HITK), a specialty pharmaceuticals company, announced today that the US Food and Drug Administration, (FDA) granted final approval for the Company's Abbreviated New Drug Application, (ANDA) for Bromfenac Ophthalmic Solution, 0.09% (Once-A-Day), the generic for ISTA Pharmaceuticals' Bromday (R) ophthalmic solution, 0.09%. The product is used to treat postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery. Hi-Tech plans to launch the product immediately.
Fish & Richardson Wins Patent Infringement Suit for Allergan Over Generic LUMIGAN® 0.01%
PR Newswire - Wed Jan 15, 3:50PM CST
Fish & Richardson announced today that it won an important Hatch-Waxman litigation for client Allergan, Inc. (NYSE: AGN) in a patent infringement suit against Sandoz Inc., Lupin Ltd., Lupin Pharmaceuticals Inc., Hi-Tech Pharmacal Co., Inc., Watson Laboratories, Inc., Watson Pharmaceuticals, Inc., and Watson Pharma, Inc. On January 14, 2014, the U.S. District Court for the Eastern District of Texas ruled that the defendants could not sell their generic versions of Allergan's popular LUMIGAN® (bimatoprost ophthalmic solution) 0.01% until Allergan's last patent expires in 2027.
Hi-Tech Pharmacal in $25M Medicaid settlement
AP - Thu Dec 26, 10:06AM CST
NEW YORK (AP) — Hi-Tech Pharmacal said Thursday that it will pay $25 million to resolve allegations that it overcharged the Texas Medicaid program.
(0)
(0)